The drug formulation market size has grown strongly in recent years. It will grow from $2.04 trillion in 2025 to $2.22 trillion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to growth in generic drug demand, rising prevalence of chronic diseases, advancements in pharmaceutical research, expansion of hospital and clinic networks, increasing investments in R&D.
The drug formulation market size is expected to see strong growth in the next few years. It will grow to $3.19 trillion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to emergence of gene and cell therapies, adoption of AI in drug design, development of novel excipients, increase in biologics and specialty drugs, expansion of emerging pharmaceutical markets. Major trends in the forecast period include personalized drug formulations, advanced drug delivery systems, biologics and biosimilars development, formulation stability and shelf-life optimization, regulatory compliance and quality assurance.
The growing adoption of personalized medicine is anticipated to drive the expansion of the drug formulation market in the coming years. Personalized medicine is an advanced healthcare strategy that customizes medical treatments and interventions according to the unique characteristics of each patient. It involves designing therapies based on individual patient factors, including genetics and biomarkers. This strategy requires the creation of customized drug formulations to enhance effectiveness and ensure patient safety. Its influence includes the demand for individualized treatment approaches, formulations that incorporate genomic data, improved drug responses, and targeted therapies for rare conditions. For example, in 2023, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, personalized medicines represented about 38 percent of all newly approved therapeutic molecular entities, increasing from 34 percent in 2022. Consequently, the rising adoption of personalized medicine is fueling the growth of the drug formulation market.
Leading companies in the drug formulation market are focusing on the development of new fixed-dose combination drugs for type 2 diabetes to strengthen their competitive position. A Fixed Dose Combination (FDC) is a pharmaceutical formulation that includes two or more active ingredients combined in a predetermined ratio within a single dosage form. For example, in October 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, introduced its first triple-drug fixed-dose combination under the brand name Zita DM. The formulation comprises the DPP4 inhibitor Teneligliptin (20 mg), the SGLT2 inhibitor Dapagliflozin (10 mg), and Metformin SR (500 mg/1000 mg) in fixed doses. It is prescribed as a once-daily medication to enhance glycemic control in patients with type 2 diabetes.
In May 2025, Roquette, a France-based supplier of plant-based ingredients and pharmaceutical excipients, acquired IFF Pharma Solutions for an undisclosed sum. Through this acquisition, Roquette seeks to reinforce its presence in the global pharmaceutical excipients market and expand its drug delivery capabilities by incorporating IFF’s innovation portfolio and technical know-how. IFF Pharma Solutions is a US-based company that designs and produces pharmaceutical excipients and specialized solutions for oral dosage forms.
Major companies operating in the drug formulation market are AstraZeneca PLC, The Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., C.H. Boehringer Sohn AG & Co. KG, F. Hoffmann-La Roche AG, Johnson & Johnson, Bayer AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, Novo Nordisk A/S, Amgen Inc., Viatris Inc., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Torrent Pharmaceuticals Limited, Jubilant Life Sciences Limited, Cadila Healthcare Limited, Glenmark Pharmaceuticals Ltd., Wockhardt Ltd., Hikma Pharmaceuticals plc.
North America was the largest region in the drug formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the drug formulation market report during the forecast period. The regions covered in the drug formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug formulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the drug formulation market by increasing the cost of imported active pharmaceutical ingredients (APIs), excipients, and specialized equipment. The impact is most pronounced in oral and parenteral formulation segments across regions like Asia-Pacific and Europe, which are key suppliers. This has prompted manufacturers to explore local sourcing, diversify suppliers, and optimize supply chains. Positive effects include incentivizing domestic production and boosting local biotech and pharmaceutical manufacturing capabilities, which could strengthen regional market resilience.
The drug formulation market research report is one of a series of new reports that provides drug formulation market statistics, including drug formulation industry global market size, regional shares, competitors with a drug formulation market share, detailed drug formulation market segments, market trends and opportunities, and any further data you may need to thrive in the drug formulation industry. This drug formulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drug formulation refers to the process of combining multiple chemical and biological components, including the active pharmaceutical ingredient, to produce a finished medicinal product. It is used to modify and optimize drugs during the preclinical phase and early-stage research.
The primary dosage form types in drug formulation include oral, parenteral, topical, and inhalation formulations. Oral formulation involves the development and manufacturing of medicines intended for oral administration. These formulations are available in various forms such as tablets, capsules, injectables, sprays, suspensions, powders, and others, and are used to treat conditions including cardiovascular diseases, pain, diabetes, cancer, respiratory disorders, and others. They are utilized by a range of end users, including large pharmaceutical companies, small and medium-sized enterprises, and biotechnology companies.
The drug formulation market includes revenues earned by entities by providing formulation optimization, process optimization, and scale-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The drug formulation market size is expected to see strong growth in the next few years. It will grow to $3.19 trillion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to emergence of gene and cell therapies, adoption of AI in drug design, development of novel excipients, increase in biologics and specialty drugs, expansion of emerging pharmaceutical markets. Major trends in the forecast period include personalized drug formulations, advanced drug delivery systems, biologics and biosimilars development, formulation stability and shelf-life optimization, regulatory compliance and quality assurance.
The growing adoption of personalized medicine is anticipated to drive the expansion of the drug formulation market in the coming years. Personalized medicine is an advanced healthcare strategy that customizes medical treatments and interventions according to the unique characteristics of each patient. It involves designing therapies based on individual patient factors, including genetics and biomarkers. This strategy requires the creation of customized drug formulations to enhance effectiveness and ensure patient safety. Its influence includes the demand for individualized treatment approaches, formulations that incorporate genomic data, improved drug responses, and targeted therapies for rare conditions. For example, in 2023, according to the Personalized Medicine Coalition (PMC), a US-based non-profit organization, personalized medicines represented about 38 percent of all newly approved therapeutic molecular entities, increasing from 34 percent in 2022. Consequently, the rising adoption of personalized medicine is fueling the growth of the drug formulation market.
Leading companies in the drug formulation market are focusing on the development of new fixed-dose combination drugs for type 2 diabetes to strengthen their competitive position. A Fixed Dose Combination (FDC) is a pharmaceutical formulation that includes two or more active ingredients combined in a predetermined ratio within a single dosage form. For example, in October 2023, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, introduced its first triple-drug fixed-dose combination under the brand name Zita DM. The formulation comprises the DPP4 inhibitor Teneligliptin (20 mg), the SGLT2 inhibitor Dapagliflozin (10 mg), and Metformin SR (500 mg/1000 mg) in fixed doses. It is prescribed as a once-daily medication to enhance glycemic control in patients with type 2 diabetes.
In May 2025, Roquette, a France-based supplier of plant-based ingredients and pharmaceutical excipients, acquired IFF Pharma Solutions for an undisclosed sum. Through this acquisition, Roquette seeks to reinforce its presence in the global pharmaceutical excipients market and expand its drug delivery capabilities by incorporating IFF’s innovation portfolio and technical know-how. IFF Pharma Solutions is a US-based company that designs and produces pharmaceutical excipients and specialized solutions for oral dosage forms.
Major companies operating in the drug formulation market are AstraZeneca PLC, The Bristol-Myers Squibb Company, Eli Lilly and Company, Gilead Sciences Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., AbbVie Inc., C.H. Boehringer Sohn AG & Co. KG, F. Hoffmann-La Roche AG, Johnson & Johnson, Bayer AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GlaxoSmithKline plc, Novo Nordisk A/S, Amgen Inc., Viatris Inc., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Limited, Torrent Pharmaceuticals Limited, Jubilant Life Sciences Limited, Cadila Healthcare Limited, Glenmark Pharmaceuticals Ltd., Wockhardt Ltd., Hikma Pharmaceuticals plc.
North America was the largest region in the drug formulation market in 2025. Asia-Pacific is expected to be the fastest-growing region in the drug formulation market report during the forecast period. The regions covered in the drug formulation market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the drug formulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the drug formulation market by increasing the cost of imported active pharmaceutical ingredients (APIs), excipients, and specialized equipment. The impact is most pronounced in oral and parenteral formulation segments across regions like Asia-Pacific and Europe, which are key suppliers. This has prompted manufacturers to explore local sourcing, diversify suppliers, and optimize supply chains. Positive effects include incentivizing domestic production and boosting local biotech and pharmaceutical manufacturing capabilities, which could strengthen regional market resilience.
The drug formulation market research report is one of a series of new reports that provides drug formulation market statistics, including drug formulation industry global market size, regional shares, competitors with a drug formulation market share, detailed drug formulation market segments, market trends and opportunities, and any further data you may need to thrive in the drug formulation industry. This drug formulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Drug formulation refers to the process of combining multiple chemical and biological components, including the active pharmaceutical ingredient, to produce a finished medicinal product. It is used to modify and optimize drugs during the preclinical phase and early-stage research.
The primary dosage form types in drug formulation include oral, parenteral, topical, and inhalation formulations. Oral formulation involves the development and manufacturing of medicines intended for oral administration. These formulations are available in various forms such as tablets, capsules, injectables, sprays, suspensions, powders, and others, and are used to treat conditions including cardiovascular diseases, pain, diabetes, cancer, respiratory disorders, and others. They are utilized by a range of end users, including large pharmaceutical companies, small and medium-sized enterprises, and biotechnology companies.
The drug formulation market includes revenues earned by entities by providing formulation optimization, process optimization, and scale-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Drug Formulation Market Characteristics
3. Drug Formulation Market Supply Chain Analysis
4. Global Drug Formulation Market Trends and Strategies
5. Drug Formulation Market Analysis of End Use Industries
7. Global Drug Formulation Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Drug Formulation Total Addressable Market (TAM) Analysis for the Market
9. Drug Formulation Market Segmentation
10. Drug Formulation Market Regional and Country Analysis
11. Asia-Pacific Drug Formulation Market
12. China Drug Formulation Market
13. India Drug Formulation Market
14. Japan Drug Formulation Market
15. Australia Drug Formulation Market
16. Indonesia Drug Formulation Market
17. South Korea Drug Formulation Market
18. Taiwan Drug Formulation Market
19. South East Asia Drug Formulation Market
20. Western Europe Drug Formulation Market
21. UK Drug Formulation Market
22. Germany Drug Formulation Market
23. France Drug Formulation Market
24. Italy Drug Formulation Market
25. Spain Drug Formulation Market
26. Eastern Europe Drug Formulation Market
27. Russia Drug Formulation Market
28. North America Drug Formulation Market
29. USA Drug Formulation Market
30. Canada Drug Formulation Market
31. South America Drug Formulation Market
32. Brazil Drug Formulation Market
33. Middle East Drug Formulation Market
34. Africa Drug Formulation Market
36. Drug Formulation Market Competitive Landscape and Company Profiles
37. Drug Formulation Market Other Major and Innovative Companies
40. Drug Formulation Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Drug Formulation Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses drug formulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for drug formulation? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug formulation market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Dosage Form: Oral formulations; Parenteral Formulations; Topical Formulations; Inhalation Formulations2) By Formulation: Tablets; Capsules; Injectable; Sprays; Suspensions; Powders; Other Formulations
3) By Therapy Area: Cardiovascular Diseases (CVDs); Pain; Diabetes; Cancer; Respiratory Diseases; Other Diseases
4) By End-User: Big Pharma; Small And Medium Pharma; Biotech Companies
Subsegments:
1) By Oral Formulations: Tablets; Capsules; Powders; Liquids Or Solutions2) By Parenteral Formulations: Injectables; Implants; Infusions
3) By Topical Formulations: Creams; Ointments; Gels; Transdermal Patches
4) By Inhalation Formulations: Metered-Dose Inhalers (MDIs); Dry Powder Inhalers (DPIs); Nebulizers
Companies Mentioned: AstraZeneca PLC; The Bristol-Myers Squibb Company; Eli Lilly and Company; Gilead Sciences Inc.; Merck & Co. Inc.; Novartis AG; Pfizer Inc.; AbbVie Inc.; C.H. Boehringer Sohn AG & Co. KG; F. Hoffmann-La Roche AG; Johnson & Johnson; Bayer AG; Teva Pharmaceutical Industries Ltd.; Sanofi S.A.; GlaxoSmithKline plc; Novo Nordisk A/S; Amgen Inc.; Viatris Inc.; Sandoz International GmbH; Takeda Pharmaceutical Company Limited; Sun Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Ltd.; Cipla Ltd.; Lupin Limited; Torrent Pharmaceuticals Limited; Jubilant Life Sciences Limited; Cadila Healthcare Limited; Glenmark Pharmaceuticals Ltd.; Wockhardt Ltd.; Hikma Pharmaceuticals plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Drug Formulation market report include:- AstraZeneca PLC
- The Bristol-Myers Squibb Company
- Eli Lilly and Company
- Gilead Sciences Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- AbbVie Inc.
- C.H. Boehringer Sohn AG & Co. KG
- F. Hoffmann-La Roche AG
- Johnson & Johnson
- Bayer AG
- Teva Pharmaceutical Industries Ltd.
- Sanofi S.A.
- GlaxoSmithKline plc
- Novo Nordisk A/S
- Amgen Inc.
- Viatris Inc.
- Sandoz International GmbH
- Takeda Pharmaceutical Company Limited
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy's Laboratories Ltd.
- Cipla Ltd.
- Lupin Limited
- Torrent Pharmaceuticals Limited
- Jubilant Life Sciences Limited
- Cadila Healthcare Limited
- Glenmark Pharmaceuticals Ltd.
- Wockhardt Ltd.
- Hikma Pharmaceuticals plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 2.22 Trillion |
| Forecasted Market Value ( USD | $ 3.19 Trillion |
| Compound Annual Growth Rate | 9.5% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
